AbCellera to present Phase 2 ABCL635 data for menopause hot flashes at IMS World Congress 2026
ABCL•Upcoming Phase 2 data presentation
AbCellera flagged upcoming Phase 2 data for ABCL635, a non-hormonal antibody for menopausal hot flashes, at the IMS World Congress on Menopause.
Results will be presented Oct. 1, 2026 in Rio de Janeiro in an oral session focused on menopausal symptoms.
Interim findings from a Phase 1/2 study are set to cover efficacy and safety in postmenopausal women with moderate-to-severe vasomotor symptoms.
The readout positions ABCL635 as a potential long-acting alternative to existing non-hormonal options, a key commercial angle in women’s health.
The Phase 2 program is a randomized, double-blind, placebo-controlled trial designed to support further clinical development decisions.
